466 related articles for article (PubMed ID: 26873451)
41. [Acromegaly: new principles for treatment].
Jørgensen JO; Feldt-Rasmussen UF; Andersen M; Kristensen LØ; Laurberg P; Weeke J
Ugeskr Laeger; 2007 Mar; 169(10):904-6. PubMed ID: 17359733
[TBL] [Abstract][Full Text] [Related]
42. The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.
Jenkins D; O'Brien I; Johnson A; Shakespear R; Sheppard MC; Stewart PM
Clin Endocrinol (Oxf); 1995 Nov; 43(5):517-22. PubMed ID: 8548933
[TBL] [Abstract][Full Text] [Related]
43. The place of pegvisomant in the acromegaly treatment algorithm.
Paisley AN; Trainer PJ; Drake WM
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
[TBL] [Abstract][Full Text] [Related]
44. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
45. How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.
van Esdonk MJ; van Zutphen EJM; Roelfsema F; Pereira AM; van der Graaf PH; Biermasz NR; Stevens J; Burggraaf J
Pituitary; 2018 Jun; 21(3):310-322. PubMed ID: 29605877
[TBL] [Abstract][Full Text] [Related]
46. Are there alternative tests for diagnosis of acromegaly?
Popovic V
J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
[TBL] [Abstract][Full Text] [Related]
47. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
48. New perspectives in the medical treatment of acromegaly.
Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
[TBL] [Abstract][Full Text] [Related]
49. Acromegaly in dogs and cats.
Gouvêa FN; Pennacchi CS; Assaf ND; Branco LO; Costa PB; Dos Reis PA; Borin-Crivellenti S
Ann Endocrinol (Paris); 2021 Apr; 82(2):107-111. PubMed ID: 33727117
[TBL] [Abstract][Full Text] [Related]
50. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
51. Advances in the pharmacotherapy of patients with acromegaly.
Fleseriu M
Discov Med; 2014 Jun; 17(96):329-38. PubMed ID: 24979253
[TBL] [Abstract][Full Text] [Related]
52. Clinical use of pegvisomant for the treatment of acromegaly.
Drake WM; Trainer PJ
Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological therapy for acromegaly: a critical review.
Muller AF; Van Der Lely AJ
Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564
[TBL] [Abstract][Full Text] [Related]
54. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective.
Patel YC; Ezzat S; Chik CL; Rorstad OP; Serri O; Ur E; Wilkins GE
Clin Invest Med; 2000 Jun; 23(3):172-87. PubMed ID: 10911548
[TBL] [Abstract][Full Text] [Related]
55. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
56. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
57. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
58. [Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición].
Cordido F; García Arnés JA; Marazuela Aspiroz M; Torres Vela E;
Endocrinol Nutr; 2013 Oct; 60(8):457.e1-457.e15. PubMed ID: 23660006
[No Abstract] [Full Text] [Related]
59. Role of insulin-like growth factor-I in diagnosis and management of acromegaly.
Clemmons DR
Endocr Pract; 2004; 10(4):362-71. PubMed ID: 15760781
[TBL] [Abstract][Full Text] [Related]
60. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.
Brabant G
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S15-20. PubMed ID: 12670296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
